Your browser doesn't support javascript.
loading
A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.
Hutten, Stefan J; de Bruijn, Roebi; Lutz, Catrin; Badoux, Madelon; Eijkman, Timo; Chao, Xue; Ciwinska, Marta; Sheinman, Michael; Messal, Hendrik; Herencia-Ropero, Andrea; Kristel, Petra; Mulder, Lennart; van der Waal, Rens; Sanders, Joyce; Almekinders, Mathilde M; Llop-Guevara, Alba; Davies, Helen R; van Haren, Matthijs J; Martin, Nathaniel I; Behbod, Fariba; Nik-Zainal, Serena; Serra, Violeta; van Rheenen, Jacco; Lips, Esther H; Wessels, Lodewyk F A; Wesseling, Jelle; Scheele, Colinda L G J; Jonkers, Jos.
Afiliação
  • Hutten SJ; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands.
  • de Bruijn R; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • Lutz C; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands.
  • Badoux M; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands.
  • Eijkman T; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands.
  • Chao X; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands.
  • Ciwinska M; Center for Cancer Biology, VIB, Department of Oncology, KU Leuven, 3000 Leuven, Belgium.
  • Sheinman M; Oncode Institute, Amsterdam, the Netherlands; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • Messal H; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands.
  • Herencia-Ropero A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain; Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, Barcelona, Spain.
  • Kristel P; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • Mulder L; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • van der Waal R; Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • Sanders J; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • Almekinders MM; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • Llop-Guevara A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Davies HR; Academic Department of Medical Genetics, School of Clinical Medicine, University of Cambridge, CB2 0QQ Cambridge, UK; Early Cancer Institute, University of Cambridge, CB2 0XZ Cambridge, UK.
  • van Haren MJ; Biological Chemistry Group, Institute of Biology Leiden, Leiden University, 2302 BH Leiden, the Netherlands.
  • Martin NI; Biological Chemistry Group, Institute of Biology Leiden, Leiden University, 2302 BH Leiden, the Netherlands.
  • Behbod F; Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS 66103, USA.
  • Nik-Zainal S; Academic Department of Medical Genetics, School of Clinical Medicine, University of Cambridge, CB2 0QQ Cambridge, UK; Early Cancer Institute, University of Cambridge, CB2 0XZ Cambridge, UK.
  • Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • van Rheenen J; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands.
  • Lips EH; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • Wessels LFA; Oncode Institute, Amsterdam, the Netherlands; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.
  • Wesseling J; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Division of Diagnostic Oncology, Netherlands Cancer Institute - Antonie van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands; Department of Pathology, Leiden University Medical Center, 2333
  • Scheele CLGJ; Center for Cancer Biology, VIB, Department of Oncology, KU Leuven, 3000 Leuven, Belgium.
  • Jonkers J; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, Amsterdam, the Netherlands. Electronic address: j.jonkers@nki.nl.
Cancer Cell ; 41(5): 986-1002.e9, 2023 05 08.
Article em En | MEDLINE | ID: mdl-37116492
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Carcinoma Intraductal não Infiltrante Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Carcinoma Intraductal não Infiltrante Idioma: En Ano de publicação: 2023 Tipo de documento: Article